|
|
|
Chairman and Chief Executive Officer
|
John Nicholson
 John has over 25 years international experience in the pharmaceutical and chemical industries, including as a CEO. He has managed and developed businesses and operations globally in the blue-chip and SME sectors. Having been involved in significant mergers & acquisitions and IPO activity, he is familiar with fund raising and the management of early-stage businesses.
|
|
|
|
|
Commercial Director
|
Dr. Steve Beasley
 Steve has over 25 years experience gained from global pharmaceutical, biotechnology and chemical companies in both research and commercial fields. He was previously COO for De Novo Pharmaceuticals responsible for all research and commercial activity and most recently Chief Executive of the knowledgebase organisation, bioKneX. He is a Chartered Chemist, a Member of the Institute of Directors and Member of the Institute of Knowledge Transfer.
|
|
|
|
|
Finance Director
|
John Yates
 As financial director of UMIST Ventures Limited and advisor to a number of start-up ventures at UMIST, John's familiarity with the unique demands of rapidly growing high-technology businesses brings valuable skills and experience to Gentronix.
|
|
|
|
|
Scientific Director and CSO
|
Prof. Richard Walmsley
 Richard is the founder and CSO of Gentronix. Richard also holds the position of Professor of Genetics at the University Manchester.
|
|
|
|
|
Director - North Amercian Operations
|
Dorothy Zelent
 Dorothy has a background in molecular biotechnology with over 10 years experience in academic and pharmaceutical research. Dorothy graduated from the University of Pennsylvania where she also conducted research into diabetes drug discovery, and joined GlaxoSmithKline as a senior scientist in cardiovascular drug discovery. Dorothy has latterly worked in project management and as Director of Business Development in a number of clinical research technology companies.
|
|
|
|
|
European Sales Director
|
Simon Johns
 Simon trained in microbiology and genetics and has over 20 years international commercial experience supporting clients in the pharmaceutical, biotechnology and chemical sectors. His early research activities involved the development of genotoxicity imaging systems, and more recently he has worked extensively within the preclinical toxicology sector for several major CROs based in Europe and the USA, providing support to clients around the world.
|
|